Renalytix AI plc

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Renalytix Plc engages in the manufacturing of medical devices and equipment. It includes the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023.

Renalytix Reports Full Year Fiscal 2023 Results

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort

Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

Commercial availability of kidneyintelX.dkd™ expanded to an estimated  4 million DKD Patients in the Middle East

Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Renalytix PLC (AIM:RENX) shares ramped 7.5% higher to 128.95p on Friday morning after it announced a distribution agreement for its kidneyintelX.dkd with Vector Pharma for the Middle East, a region that it notes has one of the highest incidence rates for type 2 diabetes globally. Commercial availability of kidneyintelX.dkd testing will be expanded to Saudi Arabia, Bahrain, Qatar, Oman, Kuwait and United Arab Emirates through the distribution agreement.

Renalytix jumps on Middle East distribution deal, 'region with most diabetes globally'

Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval and established insurance reimbursement, partnerships, and a sales team. The KidneyIntelX platform combines a blood test and data from patients' electronic health record with AI algorithms to provide a risk score for diabetic kidney disease. Despite some risks, Renalytix has the potential to reach profitability in two years if it can successfully scale its product, which could result in stock price appreciation.

Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company's Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee.

Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

Renalytix (NASDAQ: RNLX ) stock is rising higher on Friday after the medical company got marketing permission from the FDA. According to a press release from Renalytix, the FDA is allowing the company to market its KidneyIntelX.dkd prognostic test.

Why Is Renalytix (RNLX) Stock Up 45% Today?

Renalytix PLC (AIM:RENX) saw its shares surge by 38% following the US Food and Drug Administration (FDA) granting marketing authorisation for its KidneyIntelX.dkd prognostic test. This artificial intelligence-enabled platform, the first of its kind, is a major development for the care management of adults with early-stage chronic (diabetic) kidney disease and type 2 diabetes.

Renalytix shares surge on FDA green light

Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients  in the United States

FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease

Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients

KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

Renalytix plc (NASDAQ:RNLX ) Q3 2023 Results Conference Call June 9, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - CEO Tom McLain - President James Sterling - CFO Conference Call Participants Dan Arias - Stifel Chait G. - H.C. Wainwright Mark Massaro - BTIG Randy Baron - Pinnacle Operator Good morning, and welcome to the Renalytix Conference Call to Review Third Quarter Fiscal Year 2023 Financial Results.

Renalytix plc (RNLX) Q3 2023 Earnings Call Transcript

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2023.

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023

LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).

Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple Physician Specialties

New Published Real-World Evidence Shows KidneyIntelX™ Utility

In a clinical decision effectiveness study, KidneyIntelX classified more Black vs non-Black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of SGLT2-inhibitor  drug therapy

Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting

Renalytix Plc (NASDAQ:RNLX ) Q2 2023 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - CEO O. James Sterling - CFO Thomas McLain - President Fergus Fleming - CTO Conference Call Participants Daniel Arias - Stifel Unidentified Analyst - BTIG Jens Lindqvist - Investec Randy Baron - Pinnacle Associates Chaitanya Gollakota - H.C.

Renalytix Plc (RNLX) Q2 2023 Earnings Call Transcript

LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal second quarter and first half ended December 31, 2022.

Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results

LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial results on Thursday, March 30, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30

Renalytix has been fundraising successfully, extending its runway. Sales growth is strong albeit from a tiny base. Dozens of provider contracts are now in place across the U.S., though.

Renalytix: More Progress But Still Risky

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.

Renalytix announces a c.$20.3 million private placement

Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States

News for Renalytix AI plc Stock (RNLX)